Paul Choi
Stock Analyst at Goldman Sachs
(3.66)
# 754
Out of 4,955 analysts
107
Total ratings
53.62%
Success rate
6.49%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $15.85 | -24.29% | 9 | Jun 25, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $16 → $3 | $19.78 | -84.83% | 4 | May 22, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $7 → $8 | $2.17 | +268.66% | 6 | May 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $5 | $10.95 | -54.34% | 10 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Neutral | $12 → $8 | $7.30 | +9.59% | 3 | May 2, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $60 → $52 | $38.18 | +36.20% | 2 | Apr 17, 2025 | |
| VIR Vir Biotechnology | Maintains: Buy | $28 → $21 | $4.38 | +379.45% | 8 | Apr 17, 2025 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $8.11 | +47.97% | 3 | Apr 17, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Neutral | $4 → $3 | $2.13 | +40.85% | 9 | Apr 17, 2025 | |
| DVAX Dynavax Technologies | Maintains: Sell | $12 → $10 | $10.95 | -8.68% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $192.80 | +16.70% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $143 | $59.16 | +141.72% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $42 | $48.93 | -14.16% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $38.05 | +57.69% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $16.13 | +17.79% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $33.50 | -4.48% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $50.23 | -0.46% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $5.06 | +275.49% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $400 → $50 | $11.09 | +350.86% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.47 | +1,600.68% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $14.68 | +1,058.04% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $5.22 | +53.26% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $135.28 | -0.21% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $28.00 | +971.43% | 2 | Mar 30, 2020 |
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $15.85
Upside: -24.29%
UroGen Pharma
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $19.78
Upside: -84.83%
Gossamer Bio
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $2.17
Upside: +268.66%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $10.95
Upside: -54.34%
Arvinas
May 2, 2025
Maintains: Neutral
Price Target: $12 → $8
Current: $7.30
Upside: +9.59%
Xenon Pharmaceuticals
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $38.18
Upside: +36.20%
Vir Biotechnology
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $4.38
Upside: +379.45%
REGENXBIO
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $8.11
Upside: +47.97%
Esperion Therapeutics
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $2.13
Upside: +40.85%
Dynavax Technologies
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $10.95
Upside: -8.68%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $192.80
Upside: +16.70%
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $59.16
Upside: +141.72%
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $48.93
Upside: -14.16%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $38.05
Upside: +57.69%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $16.13
Upside: +17.79%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $33.50
Upside: -4.48%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $50.23
Upside: -0.46%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $5.06
Upside: +275.49%
Jun 27, 2023
Maintains: Sell
Price Target: $400 → $50
Current: $11.09
Upside: +350.86%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.47
Upside: +1,600.68%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $14.68
Upside: +1,058.04%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $5.22
Upside: +53.26%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $135.28
Upside: -0.21%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $28.00
Upside: +971.43%